Zhongzhi Pharmaceutical Holdings Limited (3737.HK)
HKD 0.89
(-2.2%)
HKD 0.89
(-2.2%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 162.77 Million CNY | 53.0% |
| 2022 | 106.38 Million CNY | 104.09% |
| 2021 | 52.12 Million CNY | -62.37% |
| 2020 | 138.53 Million CNY | 20.78% |
| 2019 | 114.69 Million CNY | 34.82% |
| 2018 | 85.06 Million CNY | 21.43% |
| 2017 | 70.05 Million CNY | 30.04% |
| 2016 | 53.87 Million CNY | -33.11% |
| 2015 | 80.53 Million CNY | -7.09% |
| 2014 | 86.68 Million CNY | 130.32% |
| 2013 | 37.63 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 83.44 Million CNY | 199.34% |
| 2023 Q2 | 134.9 Million CNY | 359.8% |
| 2023 FY | 162.77 Million CNY | 53.0% |
| 2023 Q4 | 27.87 Million CNY | -79.34% |
| 2022 FY | 106.38 Million CNY | 104.09% |
| 2022 Q2 | 77.04 Million CNY | 632.84% |
| 2022 Q4 | 29.33 Million CNY | -61.92% |
| 2021 FY | 52.12 Million CNY | -62.37% |
| 2021 Q2 | 66.58 Million CNY | 0.09% |
| 2021 Q4 | -14.46 Million CNY | -121.72% |
| 2020 Q2 | 72 Million CNY | 29.27% |
| 2020 FY | 138.53 Million CNY | 20.78% |
| 2020 Q4 | 66.52 Million CNY | -7.61% |
| 2019 FY | 114.69 Million CNY | 34.82% |
| 2019 Q4 | 55.7 Million CNY | -5.58% |
| 2019 Q2 | 58.99 Million CNY | 55.0% |
| 2018 Q2 | 47 Million CNY | 48.94% |
| 2018 FY | 85.06 Million CNY | 21.43% |
| 2018 Q4 | 38.06 Million CNY | -19.03% |
| 2017 Q2 | 38.49 Million CNY | 75.82% |
| 2017 Q4 | 31.56 Million CNY | -18.01% |
| 2017 FY | 70.05 Million CNY | 30.04% |
| 2016 Q4 | 21.89 Million CNY | -31.53% |
| 2016 FY | 53.87 Million CNY | -33.11% |
| 2016 Q2 | 31.97 Million CNY | 73.46% |
| 2015 Q4 | 18.43 Million CNY | -70.32% |
| 2015 Q2 | 62.1 Million CNY | 59.76% |
| 2015 FY | 80.53 Million CNY | -7.09% |
| 2014 FY | 86.68 Million CNY | 130.32% |
| 2014 Q2 | 47.81 Million CNY | 120.63% |
| 2014 Q4 | 38.87 Million CNY | -18.7% |
| 2013 FY | 37.63 Million CNY | 0.0% |
| 2013 Q4 | 21.67 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | -54.966% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | 91.342% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 199.893% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | 1160.009% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | 408.842% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | -874.817% |
| Essex Bio-Technology Limited | 275.25 Million HKD | 40.865% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | 664.348% |
| PuraPharm Corporation Limited | -106.08 Million HKD | 253.444% |
| SSY Group Limited | 1.31 Billion HKD | 87.656% |
| JBM (Healthcare) Limited | 130.46 Million HKD | -24.767% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | 39.028% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 95.777% |